Zurletrectinib clinical trials
Also written ICP-723.
How each study uses zurletrectinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the zurletrectinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ICP-723
- 3
Studies by the year they started
3 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
Who runs them
Industry 3 · Other 0
Beijing InnoCare Pharma Tech Co., Ltd. (2) · InnoCare Pharma Inc. (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses zurletrectinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System TumorsRecruitingPhase 1/2Beijing InnoCare Pharma Tech Co., Ltd.NCT05745623Written as ICP-723
- A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid TumorsRecruitingPhase 1/2Beijing InnoCare Pharma Tech Co., Ltd.NCT04685226Written as ICP-723
- Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid TumorsStatus unknownPhase 1InnoCare Pharma Inc.NCT05537987Written as ICP-723
Codes
What other systems call zurletrectinib · ClinicalTrials.gg INT018726
- UNII (FDA) ZVQ44E2H6VZURLETRECTINIBOne source FDA
- NCI Thesaurus C179627ZurletrectinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ZVQ44E2H6V | ZURLETRECTINIB | One source FDA |
| NCI Thesaurus | C179627 | Zurletrectinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.